PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following ...

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) is projected to post its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect PTC Therapeutics to post ...

PTC Therapeutics (PTCT) announced that the U.S. Food and Drug Administration, FDA, has accepted for filing the New Drug Application, NDA, for ...

RBC Capital analyst Brian Abrahams raised the firm’s price target on PTC Therapeutics (PTCT) to $63 from $60 and keeps an Outperform rating on ...

The U.S. Food and Drug Administration (FDA) has accepted for filing PTC Therapeutics’ New Drug Application (NDA) for ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

PTC Therapeutics (PTCT) shares rallied 9% in the last trading session to close at $50.01. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its ...

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its price objective hoisted by Royal Bank of Canada from $60.00 to $63.00 in a research report issued to clients and investors on Tuesday,Benzinga ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for vatiquinone for the ...